[Federal Register Volume 78, Number 6 (Wednesday, January 9, 2013)]
[Notices]
[Page 1848]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-00226]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Intent To Grant an Exclusive License of a U.S. Government-Owned 
Invention

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 35 U.S.C. 209(e), and 37 CFR 404.7(a)(1)(i) 
and 37 CFR 404.7(b)(1)(i), announcement is made of the intent to grant 
an exclusive, revocable license to the invention claimed in U.S. Patent 
No. 6,316,197, entitled ``Method of Diagnosing of Exposure to Toxic 
Agents by Measuring Distinct Pattern in the Levels of Expression of 
Specific Genes,'' issued on November 13, 2001, and foreign rights to 
Cascade Biotherapeutics, Inc., with its principal place of business at 
4938 Hampden Lane 319, Bethesda, Maryland 20814-2914.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For licensing issues, Dr. Paul Mele, 
Office of Research & Technology Applications, (301) 619-6664. For 
patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808; 
both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Anyone wishing to object to grant of this 
license can file written objections along with supporting evidence, if 
any, within 15 days from the date of this publication. Written 
objections are to be filed with the Command Judge Advocate (see 
ADDRESSES).

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2013-00226 Filed 1-8-13; 8:45 am]
BILLING CODE 3710-08-P